JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, S.
Right arrow Articles by Tamaki, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, S.
Right arrow Articles by Tamaki, N.
Journal of Nuclear Medicine Vol. 46 No. 4 675-682
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Biologic Correlates of Intratumoral Heterogeneity in 18F-FDG Distribution with Regional Expression of Glucose Transporters and Hexokinase-II in Experimental Tumor

Songji Zhao, MD1,2, Yuji Kuge, PhD2, Takafumi Mochizuki, MD3, Toshiyuki Takahashi, MD4, Kunihiro Nakada, MD1, Masayuki Sato, BS1, Toshiki Takei, MD1 and Nagara Tamaki, MD1

1 Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
2 Department of Tracer Kinetics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
3 Department of Radiology, Nikko Memorial Hospital, Muroran, Japan
4 Department of Pathology, Hokkaido Gastroenterology Hospital, Sapporo, Japan

The biologic mechanisms involved in the intratumoral heterogeneous distribution of 18F-FDG have not been fully investigated. To clarify factors inducing heterogeneous 18F-FDG distribution, we determined the intratumoral distribution of 18F-FDG by autoradiography (ARG) and compared it with the regional expression levels of glucose transporters Glut-1 and Glut-3 and hexokinase-II (HK-II) in a rat model of malignant tumor. Methods: Rats were inoculated with allogenic hepatoma cells (KDH-8) into the left calf muscle (n = 7). Tumor tissues were excised 1 h after the intravenous injection of 18F-FDG and sectioned to obtain 2 adjacent slices for ARG and histochemical studies. The regions of interest (ROIs) were placed on ARG images to cover mainly the central (CT) and peripheral (PT) regions of viable tumor tissues and necrotic/apoptotic (NA) regions. The radioactivity in each ROI was analyzed quantitatively using a computerized imaging analysis system. The expression levels of Glut-1, Glut-3, and HK-II were determined by immunostaining and semiquantitative evaluation. The hypoxia-inducible factor 1{alpha} (HIF-1{alpha}) was also immunostained. Results: ARG images showed that intratumoral 18F-FDG distribution was heterogeneous. The accumulation of 18F-FDG in the CT region was the highest, which was 1.6 and 2.3 times higher than those in the PT and NA regions, respectively (P < 0.001). The expression levels of Glut-1, Glut-3, and HK-II were markedly higher in the CT region (P < 0.001) compared with those in the PT region. The intratumoral distribution of 18F-FDG significantly correlated with the expression levels of Glut-1, Glut-3, and HK-II (r = 0.923, P < 0.001 for Glut-1; r = 0.829, P < 0.001 for Glut-3; and r = 0.764, P < 0.01 for HK-II). The positive staining of HIF-1{alpha} was observed in the CT region. Conclusion: These results demonstrate that intratumoral 18F-FDG distribution corresponds well to the expression levels of Glut-1, Glut-3, and HK-II. The elevated expression levels of Glut-1, Glut-3, and HK-II, induced by hypoxia (HIF-1{alpha}), may be contributing factors to the higher 18F-FDG accumulation in the CT region.

Key Words: 18F-FDG • glucose transporters • hexokinase • heterogeneity • tumor


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. A. Kidd and P. W. Grigsby
Intratumoral Metabolic Heterogeneity of Cervical Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5236 - 5241.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
J. E Burdette
In vivo imaging of molecular targets and their function in endocrinology
J. Mol. Endocrinol., June 1, 2008; 40(6): 253 - 261.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. J. Gillies, I. Robey, and R. A. Gatenby
Causes and Consequences of Increased Glucose Metabolism of Cancers
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
F. Dehdashti, P. W. Grigsby, J. S. Lewis, R. Laforest, B. A. Siegel, and M. J. Welch
Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone)
J. Nucl. Med., February 1, 2008; 49(2): 201 - 205.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. L.J. Dearling, U. Qureshi, R. H.J. Begent, and R. B. Pedley
Combining Radioimmunotherapy with Antihypoxia Therapy 2-Deoxy-D-Glucose Results in Reduction of Therapeutic Efficacy
Clin. Cancer Res., March 15, 2007; 13(6): 1903 - 1910.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
U Veronesi, C De Cicco, V. Galimberti, J. Fernandez, N Rotmensz, G Viale, G Spano, A Luini, M Intra, P Veronesi, et al.
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases
Ann. Onc., March 1, 2007; 18(3): 473 - 478.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
A Y Isa, T H Ward, C M L West, N J Slevin, and J J Homer
Hypoxia in head and neck cancer
Br. J. Radiol., October 1, 2006; 79(946): 791 - 798.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. Blaser, S. Maschauer, T. Kuwert, and O. Prante
In Vitro Studies on the Signal Transduction of Thyroidal Uptake of 18F-FDG and 131I-Iodide
J. Nucl. Med., August 1, 2006; 47(8): 1382 - 1388.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Srivastava, B. Fuchs, K. Zhang, M. Ruan, C. Halder, E. Mahlum, K. Weber, M. E. Bolander, and G. Sarkar
High WT1 Expression Is Associated with Very Poor Survival of Patients with Osteogenic Sarcoma Metastasis.
Clin. Cancer Res., July 15, 2006; 12(14): 4237 - 4243.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.